Imaging Diagnostic Systems could soon make the jump from a development-stage company to a full-fledged vendor of medical systems. The company has received regulatory approval to apply the CE Mark to its computed tomography laser mammography (CTLM) system
Imaging Diagnostic Systems could soon make the jump from a development-stage company to a full-fledged vendor of medical systems. The company has received regulatory approval to apply the CE Mark to its computed tomography laser mammography (CTLM) system and is now clear to begin marketing the product in countries in the European Union.
The CE mark is accepted in other parts of the world, the company noted, but not the U.S., where CTLM is awaiting FDA review as part of the premarket approval process. The application is expected to be complete early this year. Imaging Diagnostic Systems is seeking a PMA for the system to be used as an adjunct to conventional mammography and for clinical examination to aid in the detection of breast abnormalities.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.